Kymera Therapeutics (KYMR) Other financing activities (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Other financing activities of $425000.0 for Q1 2026, up 53.43% year-over-year from $277000.0 in Q1 2025, and down 99.13% quarter-over-quarter from $48.8 million in Q4 2025.
Kymera Therapeutics (KYMR) Other financing activities (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Other financing activities for 8 consecutive years, with $425000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 53.43% year-over-year to $425000.0; the TTM figure through Mar 2026 stood at $61.8 million (up 231.74% YoY), while the FY2025 annual figure was $61.6 million, up 3809.96% from the prior year.
- Other financing activities retreated to $425000.0 in Q1 2026 per KYMR's latest filing, from $48.8 million in the prior quarter.
- Across five years, Other financing activities topped out at $48.8 million in Q4 2025 and bottomed at -$39.1 million in Q3 2024.
- Historically, Other financing activities has averaged $4.6 million across 5 years, with a median of $277000.0 in 2025.
- Annual changes were most pronounced in 2024 — Other financing activities plunged 3266.95% — and 2025, when it jumped 707.36%.
- Kymera Therapeutics' Other financing activities stood at $2.9 million in 2022, then tumbled by 35.85% to $1.9 million in 2023, then tumbled by 532.49% to -$8.0 million in 2024, then surged by 707.36% to $48.8 million in 2025, then tumbled by 99.13% to $425000.0 in 2026.
- Business Quant data shows KYMR's Other financing activities at $425000.0 in Q1 2026, $48.8 million in Q4 2025, and $12.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.38 Mn |
| Jun 30, 2026 | 13.38 Mn |
| Mar 31, 2026 | 425,000.00 |
| Mar 31, 2026 | 425,000.00 |
| Dec 31, 2025 | 48.83 Mn |
| Dec 31, 2025 | 48.83 Mn |
| Sep 30, 2025 | 12.79 Mn |
| Sep 30, 2025 | 12.79 Mn |
| Jun 30, 2025 | -277,000.00 |
| Jun 30, 2025 | -277,000.00 |
| Mar 31, 2025 | 277,000.00 |
| Mar 31, 2025 | 277,000.00 |
| Dec 31, 2024 | -8.04 Mn |
| Dec 31, 2024 | -8.04 Mn |
| Sep 30, 2024 | -39.12 Mn |
| Sep 30, 2024 | -39.12 Mn |
| Mar 31, 2024 | 48.74 Mn |
| Mar 31, 2024 | 48.74 Mn |
| Dec 31, 2023 | 1.86 Mn |
| Dec 31, 2023 | 1.86 Mn |